Thera-SAbDab

TISLELIZUMAB

>   Structural Summary
TherapeuticTislelizumab
TargetPDCD1
Heavy ChainQVQLQESGPGLVKPSETLSLTCTVSGFSLTSYGVHWIRQPPGKGLEWIGVIYADGSTNYNPSLKSRVTISKDTSKNQVSLKLSSVTAADTAVYYCARAYGNYWYIDVWGQGTTVTVSS
Light ChainDIVMTQSPDSLAVSLGERATINCKSSESVSNDVAWYQQKPGQPPKLLINYAFHRFTGVPDRFSGSGYGTDFTLTISSLQAEDVAVYYCHQAYSSPYTFGQGTKLEIK
100% seqID Fv Structure7bxa [Fvs: BC, HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG4
Highest Clinical Trial (June '19)Preregistration
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2017
INN Year Recommended2018
Companies InvolvedBeiGene, Celgene Corporation
Conditions Approvedna
Conditions ActiveHodgkin's disease, Gastric cancer, Liver cancer, Nasopharyngeal cancer, Non-small cell lung cancer, Oesophageal cancer, Lung cancer, Lymphoma, Urogenital cancer, Solid tumours, Ovarian cancer, Renal cancer
Conditions Discontinuedna
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]